{'fraction_non_alphanumeric': 0.02009273570324575, 'fraction_numerical': 0.0, 'mean_word_length': 6.280898876404494, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Living-Donor Kidney Transplant-Associated Thrombotic Microangiopathy Successfully Treated With Thymoglobulin: A Case Report.

Transplantation is the ultimate therapy for end-stage kidney disease. Early graft dysfunction is a devastating event to patients and carries risk of graft loss. Medical causes of early graft loss include graft rejection, drug toxicity, and thrombotic microangiopathy. Here, we report a case of posttransplant thrombotic microangiopathy associated with cellular vascular rejection. Thymoglobulin successfully reversed vascular rejection and thrombotic microangiopathy associated with half dosing of calcineurin inhibitors.